Immunize.org and Autism Science Foundation: vaccines are not linked to autism
Immunize.org and the Autism Science Foundation updated their evidence resource confirming no causal link between autism and vaccines, including MMR and thimerosal-containing vaccines. The update also covers immune system capacity, known genetic/environmental risk factors, and includes supporting PDFs now available on HCP Vaccine Updates.
Read more on Vaccine Updates →حملة تطعيم ضد شلل الأطفال
حملة تطعيم ضد شلل الأطفال من يوم ١٩ أبريل ولمدة ٤ أيام. الحملة مجانية وتستهدف الأطفال من عمر يوم حتى ٥ سنوات. الحملة محدودة وفي السادس من أكتوبر والشيخ زايد بمحافظة الجيزة.
لمعرفة معلومات أكثر عن التطعيم اضغط هنا ←PCV13 study in pediatric IBD: 2-year prospective findings
A new Expert Review of Vaccines study reports that a single PCV13 dose was not associated with increased inflammatory bowel disease activity in children and adolescents over 24 months, with similar exacerbation rates versus controls. The full study PDF is now available on the HCP Vaccine Updates page.
Read more on Vaccine Updates →FDA expands GSK's Arexvy license to include high-risk adults 18 to 49 years
FDA expanded the indicated age range for Arexvy to include adults age 18 through 49 years at increased risk for RSV lower respiratory tract disease. The update notes Arexvy should not be used during pregnancy, and that RSV vaccine recommendations are pending due to the stay of ACIP activities.
Read more on Vaccine Updates →American Academy of Family Physicians: 2026 immunization schedules
The AAFP has published its 2026 recommended immunization schedules for birth through 18 years and for adults—aligned with the AAP childhood schedule and with targeted updates to the adult schedule. On our HCP Vaccine Updates page you can read the summary and open or download the official AAFP schedule PDFs.
Read more on Vaccine Updates →New GSK Pentavalent Meningococcal Vaccine Endorsed by ACIP
CDC's Advisory Committee on Immunization Practices (ACIP) endorsed a new GSK pentavalent meningococcal vaccine (MenACWY-CRM/MenB-4C, Penmenvy) for use in people aged ≥10 years when both MenACWY and MenB are indicated. The recommendation highlights implementation efficiency, equity, and real-world feasibility. Serious adverse events were rare and occurred at similar frequencies in pentavalent and control groups. Using pentavalent vaccine as an alternative to concomitant administration was the most cost-saving option.
Read More →أعلنت شركة فايزر مصر عن طرح لقاح للوقاية من الإصابة بالفيروس المخلوي التنفسي (RSV)
أعلنت شركة فايزر مصر عن طرح لقاح للوقاية من الإصابة بالفيروس المخلوي التنفسي (RSV). هذا اللقاح يمثل تطورًا مهمًا في مجال الوقاية من الأمراض التنفسية في مصر.
اقرأ المزيد ←Immunize.org and Autism Science Foundation: vaccines are not linked to autism
Immunize.org and the Autism Science Foundation updated their evidence resource confirming no causal link between autism and vaccines, including MMR and thimerosal-containing vaccines. The update also covers immune system capacity, known genetic/environmental risk factors, and includes supporting PDFs now available on HCP Vaccine Updates.
Read more on Vaccine Updates →حملة تطعيم ضد شلل الأطفال
حملة تطعيم ضد شلل الأطفال من يوم ١٩ أبريل ولمدة ٤ أيام. الحملة مجانية وتستهدف الأطفال من عمر يوم حتى ٥ سنوات. الحملة محدودة وفي السادس من أكتوبر والشيخ زايد بمحافظة الجيزة.
لمعرفة معلومات أكثر عن التطعيم اضغط هنا ←PCV13 study in pediatric IBD: 2-year prospective findings
A new Expert Review of Vaccines study reports that a single PCV13 dose was not associated with increased inflammatory bowel disease activity in children and adolescents over 24 months, with similar exacerbation rates versus controls. The full study PDF is now available on the HCP Vaccine Updates page.
Read more on Vaccine Updates →FDA expands GSK's Arexvy license to include high-risk adults 18 to 49 years
FDA expanded the indicated age range for Arexvy to include adults age 18 through 49 years at increased risk for RSV lower respiratory tract disease. The update notes Arexvy should not be used during pregnancy, and that RSV vaccine recommendations are pending due to the stay of ACIP activities.
Read more on Vaccine Updates →American Academy of Family Physicians: 2026 immunization schedules
The AAFP has published its 2026 recommended immunization schedules for birth through 18 years and for adults—aligned with the AAP childhood schedule and with targeted updates to the adult schedule. On our HCP Vaccine Updates page you can read the summary and open or download the official AAFP schedule PDFs.
Read more on Vaccine Updates →New GSK Pentavalent Meningococcal Vaccine Endorsed by ACIP
CDC's Advisory Committee on Immunization Practices (ACIP) endorsed a new GSK pentavalent meningococcal vaccine (MenACWY-CRM/MenB-4C, Penmenvy) for use in people aged ≥10 years when both MenACWY and MenB are indicated. The recommendation highlights implementation efficiency, equity, and real-world feasibility. Serious adverse events were rare and occurred at similar frequencies in pentavalent and control groups. Using pentavalent vaccine as an alternative to concomitant administration was the most cost-saving option.
Read More →أعلنت شركة فايزر مصر عن طرح لقاح للوقاية من الإصابة بالفيروس المخلوي التنفسي (RSV)
أعلنت شركة فايزر مصر عن طرح لقاح للوقاية من الإصابة بالفيروس المخلوي التنفسي (RSV). هذا اللقاح يمثل تطورًا مهمًا في مجال الوقاية من الأمراض التنفسية في مصر.
اقرأ المزيد ←